The US Food and Drug Administration is carefully treading a line between product quality and availability by allowing imports of two oft-curative generic cancer drugs from an Indian plant to stem serious shortages that followed a disastrous inspection, but only with strict oversight reminiscent of consent decree terms.
The agency spelled out the arrangement in an unusual import alert notification letter that it posted 2 June amid an...





